Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients ...

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen ...

Testosterone therapy after prostate cancer surgery does not appear to increase biochemical recurrence (BCR) risk in patients with low-risk disease, investigators report.

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

Testosterone replacement therapy may not increase prostate cancer recurrence risk, but evidence remains inconclusive, necessitating individualized treatment plans. Bipolar androgen therapy (BAT) ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...